PR Newswire
RONKONKOMA, N.Y., May 12, 2024
In a significant stride for urological health, Rigicon Inc. proudly announces groundbreaking enhancements to its ContiReflex® artificial urinary sphincter and Testi10 testicular prosthesis. These state-of-the-art developments, recently showcased at the American Urological Association meeting and featured in the International Journal of Impotence Research, mark a pioneering leap in medical technology. With the latest ContiReflex® model, Rigicon introduces a novel dual-bladder system, designed to offer unmatched control and comfort for patients suffering from male stress incontinence. Meanwhile, the Testi10 testicular prosthesis sets a new standard in prosthetic reliability and patient safety, achieving a remarkable 99.8% survival rate over 54 months. Rigicon's commitment to innovation and patient care continues to redefine industry standards and improve the quality of life for patients globally.
RONKONKOMA, N.Y., May 12, 2024 /PRNewswire-PRWeb/ -- Rigicon Inc., a pioneering medical device company, today announced significant advancements in its ContiReflex® artificial urinary sphincter and Testi10TM testicular prosthesis lines, showcased in recent high-profile scientific forums.
ContiReflex®: Innovations in Managing Male Incontinence
The new generation ContiReflex® artificial urinary sphincter introduces a dual-bladder system in its pressure regulating balloon (PRB) to effectively manage male stress incontinence, particularly following radical prostatectomy. This technology was recently detailed in a paper presented at the prestigious American Urological Association (AUA) meeting, signaling a major leap forward in patient care.
Key Enhancements and Clinical Data:
Testi10: Setting New Standards in Testicular Prosthetics
Rigicon's Testi10 testicular prosthesis has been recognized for its exceptional reliability and safety in a comprehensive study published in the International Journal of Impotence Research. The study, involving 427 patients, demonstrated a survival rate of 99.8% over 54 months, affirming the prosthesis's superior design and performance.
Device Features and Performance Insights:
A Dedication to Clinical Excellence and Patient Outcomes:
"These significant milestones, achieved through rigorous research and peer-reviewed by the global medical community, underscore our commitment to innovation and excellence in patient care," said Professor Steven K Wilson, Global Medical Director at Rigicon. "Presenting our findings at the AUA meeting and publishing in a respected journal are testaments to the scientific validity and potential impact of our products."
Rigicon remains at the forefront of urological health, driving advancements that redefine treatment standards and improve patient lives worldwide.
Media Contact
Savas Karaoglu, Rigicon Inc, 1 8882029790, [email protected], www.rigicon.com
View original content to download multimedia:https://www.prweb.com/releases/rigicon-announces-groundbreaking-advances-in-prosthetic-urology-with-contireflex-and-testi10-testicular-prosthesis-302142872.html
SOURCE Rigicon Inc
We use cookies to tailor your experience, measure site performance and present relevant offers and advertisements. By clicking ‘Accept’ or any content on this site, you agree that cookies can be placed on your browser. You can view our privacy policy to learn more.
If you would like to get more data, alerts and access to Real Vision videos, join us as an Insider Tracking Advantage Ultra member